RNCOS has recently launched a new report “Cancer Generics Market Analysis”. Cancer has emerged as one of the major causes of death globally and has made the pharmaceutical & biotech companies proactive to foray research & development to develop new therapies for its treatment. With increasing cancer incidences and competition in the healthcare industry around the world, the cancer market represents a lucrative sector for the generic players around the world due to the fact that price erosion is significantly lower than the other segments.
According to our new research report, “Cancer Generics Market Analysis”, the global cancer generics market is anticipated to grow at a CAGR of around 27% during 2010-2014. Market growth will be driven by upcoming anti-cancer blockbuster drugs patent expirations and the rising drugs bill that will encourage payers to address the barriers to generics access in order to control costs. As per our research, oncology drugs worth around US$10 Billion are expected to lose patent rights in the US by 2011. As the governments and private players have stepped in the industry across various geographical locations, the future prospects of the market shows immense opportunities to tap on.
Our thorough study on the industry indicates that the Global Cancer generics drugs industry has witnessed a number of product launches and mergers & acquisitions in the past few years. The main focus of the companies has been to introduce effective and quality products in the market so that it gains a worldwide acceptance. With new markets and new products for generics manufacturers within the cancer market, it is anticipated that a harsh environment for companies focusing on novel cancer treatments is about to come. However, within the cancer market, there remains a high level of unmet need, and novel products demonstrating improved clinical attributes to any degree that would be expected to capture the market share from older generic drugs.
On the competitive front, Teva & Hospira are presently the global market leader in cancer generics drugs market. Meanwhile, some Indian companies are also using their experiences within the deregulated markets to produce dossiers and products suited for the regulated markets.
The report provides extensive information and rational analysis of the global cancer generics drugs market. It has thoroughly examined current market drivers, industrial developments, and competitive landscapes to enable clients understand the market structure and its progress in the coming years. The report also provides an insight into different marketed products along with pipeline analysis to present an overview of the developments taking place in the global cancer generics drugs industry. Further, a review of product innovations and recent industry activity has also been covered in the report.
Established in 2002, RNCOS is a premier source of industry research and information provider. We bring first-hand information and prudent analysis on different industries, technologies, economic and non-economic market parameters, potential markets, and key competitors, to help clients identify prospective growth areas and gain competitive edge.
Article By: Sara Matthews